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Abstract 
Oxytocin has repeatedly been shown to influence human behavior in social contexts; also, a 
relationship between oxytocin and the pathophysiology of Autism Spectrum Disorder (ASD) has been 
suggested. In the present study, we investigated SNPs in the oxytocin gene (OXT), and the genes for 
single-minded 1 (SIM1), aryl hydrocarbon receptor nuclear translocator 2 (ARNT2), and cluster of 
differentiation 38 (CD38), in a population of 1771 children from the Child and Adolescent Twin Study 
in Sweden. Statistical analyses were performed to investigate any association between SNPs and 
autistic-like traits (ALTs), measured through ASD scores in the Autism-Tics, ADHD and other Co-
morbidities inventory. Our main finding was a statistically significant association between the SIM1 
SNP rs3734354 (Pro352Thr) and ASD scores for language impairment (p=0.0004). Furthermore, 
nominal associations were found between ASD scores and SNPs in OXT, ARNT2 and CD38. In 
summary, the present study lends support to the hypothesis that oxytocin and oxytocin neuron 
development may have an influence on the development of ALTs, and suggests a new candidate gene 
in the search for the pathophysiology of ASD. 
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Highlights: 
 We examined SNPs in oxytocin-related genes, in relation to autistic-like traits 
 A SIM1 SNP was associated with autistic-like traits, primarily language impairment 
 SNPs in OXT, ARNT2 and CD38 showed nominal associations with autistic-like traits 
 
 
 
 
 
 
 
Introduction 
Patients with Autism Spectrum Disorder (ASD) are characterized by three core symptom dimensions: 
language impairment, impairment of social interaction and communication, and restrictive and 
repetitive behavior (American Psychiatric Association. and American Psychiatric Association. Task 
Force on DSM-IV., 1994). Studies of autistic-like traits (ALTs) have suggested that an ASD diagnosis 
represents the extreme lower end of normally distributed abilities for social communication 
(Constantino et al., 2004; Posserud et al., 2006). The importance of genetic factors in the etiology of 
ASD has repeatedly been demonstrated in twin studies, with heritability estimates of 70-90% (Bailey 
et al., 1995; Lichtenstein et al., 2010; Rosenberg et al., 2009). Moreover, ALTs and ASD have been 
shown to share common genetic influences (Lundstrom et al., 2012; Robinson et al., 2011). The 
theoretical division into the three symptom dimensions mentioned above has been confirmed in 
several studies (Happe and Ronald, 2008), and these domains have been indicated to have partly 
separate genetic influences when investigated in the general population (Ronald et al., 2011). 
Furthermore, it has been demonstrated that girls and boys display different ALTs, both among ASD 
patients (Mandy et al., 2012) and among children who do not meet diagnostic criteria for ASD 
(Dworzynski et al., 2012). 
 
Oxytocin is a neuropeptide primarily produced in magnocellular neurons of the paraventricular (PVN) 
and supraoptic nuclei (SON) of the hypothalamus. The major part of oxytocin is transported to the 
posterior pituitary, where it is released into the general circulation, but a smaller part is released into 
the brain via magnocellular dendrites (Ludwig and Leng, 2006) and oxytocin-releasing neurons 
projecting to specific brain areas, including the amygdala (Knobloch et al., 2012). Oxytocin has, aside 
from its established roles in lactation and parturition, been implicated in regulation of social behavior 
(Donaldson and Young, 2008). In rodents, oxytocin is involved in social interaction, social 
recognition, pair bonding and maternal behavior (Neumann, 2008). Several studies have been 
conducted under the hypothesis that this influence also exists in humans, and oxytocin has been shown 
to be associated with face recognition and formation of affiliative bonds (Lee et al., 2009), and 
concentrations of oxytocin in cerebrospinal fluid of newborns have showed a positive correlation with 
interest in social engagement with others (Clark et al., 2013). The suggestion that oxytocin plays a role 
in human social interaction has inspired the hypothesis that it may also be involved in the phenotypes 
of ASD, and it has been shown that plasma oxytocin levels in children with autism are lower than in 
controls (Modahl et al., 1998). Additionally, adults with classic autism and Asperger’s syndrome, 
given intravenous infusions of oxytocin, experience reduced number and severity of repetitive 
behaviors (Hollander et al., 2003) and increased ability to remember affective components of spoken 
words (Hollander et al., 2007). Intranasally administered oxytocin has been shown to increase emotion 
recognition in young patients with ASD (Guastella et al., 2010) and to improve social cognition 
(Anagnostou et al., 2012) and influence amygdala activation in the processing of facial stimuli in ASD 
patients (Domes et al., 2013). Furthermore, several studies have indicated that single nucleotide 
polymorphisms (SNPs) in the oxytocin (OXT) and oxytocin receptor genes are associated with ASD 
(Ebstein et al., 2012). 
 
Single-minded 1 (SIM1) is a transcription factor required for the terminal differentiation of 
neuroendocrine neurons in the PVN and SON (Michaud et al., 1998). It has so far been studied mainly 
with a focus on hyperphagia and obesity, with an effect demonstrated by mice haploinsufficient for the 
SIM1 gene (Xi et al., 2012). It has been shown that SIM1 is important for oxytocin expression in the 
PVN, with a near 80% reduction in haploinsufficient mice (Kublaoui et al., 2008). In the PVN and 
SON, SIM1 is co-expressed with the transcription factor aryl hydrocarbon receptor nuclear 
translocator 2 (ARNT2). The loss of ARNT2 function also affects the development of the same 
neuroendocrine cell lines within the PVN and SON influenced by SIM1 (Michaud et al., 2000). 
Interestingly, SNPs in the human ARNT2 gene have been associated with ASD (Chakrabarti et al., 
2009). 
 
Cluster of differentiation 38 (CD38) is a type II transmembrane protein associated with normal social 
behavior in mice (Jin et al., 2007), and has been shown to play an important role in the process of 
oxytocin release in the hypothalamus in mice, with CD38 disruption yielding impairment of maternal 
behavior and social recognition, similar to the behavior seen in OXT knockout mice (Higashida et al., 
2011). In humans, there have been indications that SNPs in the CD38 gene are associated with reduced 
oxytocin plasma levels and ASD symptoms, as well as effects on visual processing of, and fusiform 
gyrus activation by, social stimuli (Munesue et al., 2010; Sauer et al., 2012). 
 
In this study, we considered the above genes (OXT, SIM1, ARNT2 and CD38) as possible candidate 
genes influencing ALTs in the general population, given the implications for a possible oxytocin 
influence on the symptoms of ASD, and the potential influence of the genes SIM1, ARNT2, and CD38 
on oxytocin release and neuron development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods and Materials 
Participants 
The Child and Adolescent Twin Study in Sweden (CATSS) is an ongoing study since July 2004 that 
targets all twins born in Sweden since July 1992, at 9 or 12 years of age. The study has a response rate 
of 80%, making it a highly representative population sample (Anckarsater et al., 2011). At present, 
data has been collected on 12,446 children: n=5,944 9-year-olds and 6496 12-year-olds. The present 
study used genetic material from the first DNA collection from CATSS (both 9- and 12-year-olds), 
including information on a total of 1771 individuals from the CATSS population (887 girls and 884 
boys). This cohort has been used in previous genetic association studies (Walum et al., 2012). Since 
the sample was recruited from the general population, it contains the full variation of ALTs, including 
those meeting the criteria for a clinical diagnosis of ASD and other neuropsychiatric disorders. The 
focus of our study was to investigate the possible influence of common genetic variations in OXT, 
SIM1, CD38 and ARNT2 on ALTs – hence, 24 individuals were excluded from the analyses due to 
either documented brain damage (most commonly cerebral palsy) or a known genetic syndrome (most 
commonly Down syndrome but also Fragile X syndrome), since individuals with these conditions are 
known to display a high degree of autism-related symptoms (Zafeiriou et al., 2007). The final number 
of individuals used in the statistical analyses (n=1747) included 357 monozygotic (MZ) twin pairs, 
500 dizygotic (DZ) twin pairs and 33 individuals without their co-twin. Zygosity was determined 
using a panel of 47 SNPs (Hannelius et al., 2007). Although all statistical analyses (see below) were 
adjusted for kinship, the population is analyzed as a representative sample of children from the general 
population in Sweden. The CATSS study has been approved by the Karolinska Institutet Ethical 
Review Board (No. 02-289), and informed consent was provided by all participants. The present study 
was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration 
of Helsinki) for experiments involving humans. 
 
Measurements 
The parents of all twins were contacted when their twins turned 9 or 12 years old, and asked to 
participate in a telephone interview containing, among other instruments, the Autism-Tics, ADHD and 
other Co-morbidities inventory (A-TAC) (Hansson et al., 2005; Larson et al., 2010). The A-TAC is a 
tool for screening general populations for child ASD and related conditions, and can also be used as a 
dimensional measure of ALTs, reflecting the continuous character of the autism spectrum. It has a 
high sensitivity and specificity (0.96 and 0.88, respectively) for predicting a clinical diagnosis of ASD 
(Hansson et al., 2005; Larson et al., 2010). The 17 questions on ALTs, 12 of which specifically 
address the DSM-IV criteria for autistic disorder, reflect the three core symptom dimensions of autism, 
represented as modules: language impairment (six questions), social interaction impairment (six 
questions) and restrictive/repetitive behavior (five questions). Each item has three response categories: 
“No” (coded 0), “Yes, to some extent” (coded 0.5) and “Yes” (coded 1). The measure of total ASD 
scores is the sum of the 17 items. The A-TAC is freely available from the Internet as an appendix to 
the published article by Larson et al. (Larson et al., 2010). It has previously been used as a 
dimensional measure of ALTs in a genetic association study (Walum et al., 2012), and in several 
studies investigating the heritability of (Lundstrom et al., 2012), and relation between, different 
neurodevelopmental and behavioral problems in children from the general population (Lichtenstein et 
al., 2010; Lundstrom et al., 2011). 
 
Genotyping 
DNA was extracted from saliva samples using OraGene® DNA self-collection kit (DNA Genotek, 
Inc., Ottawa, Ontario, Canada). Nine single nucleotide polymorphisms (SNPs) in OXT, SIM1, ARNT2 
and CD38 were genotyped with KASPar® PCR SNP genotyping system (KBiosciences, Herts, UK). 
The SNPs were chosen based on previous results from genetic association studies on ASD and related 
phenotypes, in an attempt to further investigate these in relation to ALTs, with the exception of 
rs3734354 (SIM1), rs4072568 (ARNT2), and rs6449182 (CD38), which were chosen based on their 
relationship to oxytocin regulation and that these particular SNPs have been shown to be functional 
(Jamroziak et al., 2009; Swarbrick et al., 2011). The SNPs chosen for genotyping are listed in Table 1, 
with further information regarding positions, minor allele frequencies (MAF) and the previous studies 
reporting associations with ASD symptoms, or SNP effects on functionality. The genotyping success 
rate was >97%. All the SNPs were found to be in Hardy-Weinberg equilibrium (p ˃ 0.05), which was 
calculated using one subject in each monozygotic twin pair and all of the dizygotic twins.  
 
Statistical Analyses 
Statistical associations between SNPs and continuous measures of ALTs, including the A-TAC 
modules for language impairment, social interaction impairment, and restricted and repetitive 
behavior, were estimated using a linear mixed effect model in the MIXED procedure (PROC MIXED) 
of SAS 9.3 (SAS Institute, Inc., Cary, NC, USA). This model allows adjustment for the dependent 
nature of the twin observations (i.e. A-TAC scores from all genotyped subjects were included in the 
analyses). Given that monozygotic twins, on average, share 100% of their genome while dizygotic 
twins only share 50% of their genome, and that monozygotic twins are more similar that dizygotic 
twins in ALT scores (Lundstrom et al., 2012), we modeled two separate variance-covariance matrices: 
(1) for monozygotic twins, and (2) for dizygotic twins. By using R-side random effects with an 
unstructured variance-covariance matrix, correlations between individuals in group (1) and (2) were 
calculated. The sample size made it possible to analyze girls and boys separately. Mean scores and 
standard deviations were calculated using the MEANS procedure (PROC MEANS) in SAS 9.3. To 
control for multiple testing, Bonferroni correction was performed: analyses of nine SNPs, three 
module scores and two sexes separately, yielding 54 independent tests, resulting in a corrected p-value 
limit of 0.0009. 
 
 
 
 
 
 
 
 
 
Results 
Associations between SNPs and ALTs, or any of the modules for language impairment, social 
interaction impairment or restrictive/repetitive behavior, are shown in Table 2. The most significant 
result was found in boys, between the SIM1 SNP rs3734354 and total ASD scores, as well as social 
interaction impairment, and language impairment, where the T-allele homozygotes were shown to 
have higher scores. The association with language impairment (p=0.0004) survived Bonferroni 
correction. Based on the mean scores of the three genotypes, we assumed that the effect was recessive, 
and conducted a post-hoc analysis under a recessive model (TT vs. GT/GG), resulting in a p-value of 
0.00009. In girls, the OXT SNP rs2770378 showed nominal association with total ASD scores, 
language impairment, and restricted behavior. These associations did not, however, survive correction 
for multiple testing. Nominal associations were also found for the SNPs rs3901896 in ARNT2 (risk 
allele T) and rs6449182 in CD38 (risk allele C). We found no significant associations with ALTs for 
SNPs rs2740204 (OXT), rs6133010 (OXT), rs3796863 (CD38), rs4072568 (ARNT2) or rs4778599 
(ARNT2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The main finding of the present study was an association between language impairment and the TT 
genotype of the SIM1 SNP rs3734354 in boys. This SNP was also nominally associated with total 
ASD scores and social interaction impairment. SIM1 has been previously studied for associations with 
obesity and hyperphagia, with a demonstrated lowering of hypothalamic oxytocin mRNA expression 
(Xi et al., 2012) and oxytocin peptide levels (Kublaoui et al., 2008) in SIM1 haploinsufficient mice. 
Swarbrick and co-workers extended these findings to humans by demonstrating that the T allele of 
rs3734354) is associated with a 22% decreased transcriptional activity and the TT genotype to be 
associated with adiposity in males (Swarbrick et al., 2011). Taken together with our results these 
findings supports the view that the TT genotype of the SIM1 SNP rs3734354 contribute to lower 
oxytocin levels, which may have consequences for behavioral as well as for peripheral phenotypes. To 
our knowledge, our study is the first to investigate this SIM1 SNP with respect to continuous scores for 
ASD-related phenotypes. In previous GWAS studies, only one (Ronald et al., 2010) has investigated 
ASD in this manner, and this SNP was not genotyped by the array used in that study (Affymetrix 
500K). Other GWA studies (Anney et al., 2012; Anney et al., 2010; Ma et al., 2009; Wang et al., 
2009; Weiss et al., 2009), comparing diagnosed ASD patients with healthy controls, did indeed 
include rs3734354, and reported no associations at the GWAS level. Taken together with our results, 
this may indicate that SIM1 plays a part in ALTs, rather than effecting an actual diagnosis. 
 
We also found nominally significant associations between the OXT SNP rs2770378 and ALTs for 
girls, specifically for the language impairment and restricted behavior modules. In previous studies, 
Chakrabarti et al. found an association between rs2770378 and ASD diagnosis (Chakrabarti et al., 
2009), while Yrigollen et al., in contrast with our results, found no association with ASD on a number 
of assessment scales (Yrigollen et al., 2008). Neither of these studies performed sex-specific analyses. 
Furthermore, we were not able to replicate the association between rs2740204 and stereotypic 
behaviors presented by Yrigollen et al. in the above study, nor were we able to find any association 
between ALTs and the OXT SNP rs6133010, previously associated with ASD in a study by Ebstein et 
al. (Ebstein et al., 2009). 
 It is somewhat puzzling that we were able to associate OXT with ALTs in girls, but SIM1 in boys, 
given that our hypothesis included SIM1 as a regulator of oxytocin neuron development. However, one 
may consider that SIM1 not only influences oxytocin neurons in the hypothalamus, but arginine 
vasopressin neurons as well (Duplan et al., 2009), and that it has been indicated that vasopressin 
activity is associated with social behavior, e.g. through influences on male parental behavior (Wang et 
al., 1998) and male pair bond formation in voles (Cho et al., 1999) and humans (Walum et al., 2012). 
Furthermore, a strong sexual dimorphism for the roles of oxytocin and vasopressin has been 
established, indicating a more important role of vasopressin in males for social recognition (de Vries, 
2008). There is a possibility that this sexual dimorphism can explain the male-specific association of 
the SIM1 SNP, as well as the female-specific importance of OXT. 
 
We also found significant effects of the ARNT2 SNP rs3901896 in girls on language impairment. 
Although this result did not survive correction for multiple testing, it has previously been investigated 
by Chakrabarti et al. (Chakrabarti et al., 2009) – albeit they found an association by a case-control 
analysis. We were not able to replicate their finding of the ARNT2 SNP rs4778599, where an 
association in their case was seen with scores on the Autism Spectrum Quotient scale. 
 
Finally, we found an association between rs6449182 in CD38 and language impairment scores, not 
obviously specific for either gender. Two independent studies have shown that carriers of the G allele 
have higher CD38 mRNA transcript levels and a higher proportion of CD38-positive cells (Jamroziak 
et al., 2009; Polzonetti et al., 2012). A study by Riebold et al. suggested associations between CD38 
transcription levels in general and IQ, as well as scores on the Vineland Adaptive Behavior Scales 
(specifically the scales for social skills and communication) (Riebold et al., 2011). If, indeed, the 
transcription levels are increased by the G allele, these two findings taken together would be in line 
with our results, where homozygotic carriers of the G allele scored lower for ALTs related to language 
impairment. We were not able to find any statistical association between ALTs and rs3796863, a 
CD38 SNP previously investigated by Munesue et al., finding an association with ASD in a clinical 
subset (Munesue et al., 2010), and Sauer et al., finding an association with fusiform gyrus activation 
(implicated in ASD research) (Sauer et al., 2012). 
 
In conclusion, this study suggests an association between an exonic SIM1 SNP and ALTs in children 
from the general population. Given that the relevant homozygote variation mentioned above is 
relatively rare, however, further research is needed to support this before any conclusions may be 
drawn. Furthermore, we have extended previous investigations into SNPs from OXT, ARNT2 and 
CD38. However, the results are not conclusive, and should be interpreted with caution, as previous 
findings, as well as our results, may be coincidental. 
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Table 1. SNP details 
Gene Chromosome SNP Location MAF Reference 
OXT 20p13 rs2740204 Downstream 0.40 (T) Yrigollen et al. 2008; Chakrabarti et al. 2009 
  rs2770378 Downstream 0.40 (A) Yrigollen et al. 2008; Chakrabarti et al. 2009 
  rs6133010 Upstream 0.11 (G) Ebstein et al. 2009 
SIM1 6q16.3 rs3734354 Exon 0.14 (T) Swarbrick et al. 2011 
CD38 4p15.32 rs3796863 Intron 0.31 (A) Munesue et al. 2010, Sauer et al. 2012 
  rs6449182 Intron 0.22 (G) Jamroziak et al. 2009, Riebold et al. 2011 
ARNT2 15q25.1 rs3901896 Intron 0.39 (T) Chakrabarti et al. 2009 
  rs4072568 Exon 0.20 (A) Swarbrick et al. 2011 
    rs4778599 Intron 0.33 (A) Chakrabarti et al. 2009 
 
  
Table 2. Associations between SNPs in OXT and OXT-related genes and ALTs 
SNP   Total ASD symptoms Language impairment Social interaction impairment Restricted behaviour 
    Mean score (SD) Mean score (SD) Mean score (SD) Mean score (SD) 
  n All Boys Girls All Boys Girls All Boys Girls All Boys Girls 
OXT rs2770378 A/A(289) 0.93 (1.66) 1.21 (1.98) 0.65 (1.23) 0.33 (0.69) 0.40 (0.82) 0.26 (0.52) 0.33 (0.66) 0.40 (0.74) 0.27 (0.57) 0.26 (0.68) 0.40 (0.84) 0.13 (0.44) 
A/G(789) 0.87 (1.77) 1.22 (2.07) 0.52 (1.33) 0.28 (0.67) 0.41 (0.82) 0.16 (0.47) 0.31 (0.71) 0.41 (0.83) 0.21 (0.56) 0.28 (0.66) 0.40 (0.78) 0.16 (0.48) 
G/G(636) 1.05 (2.01) 1.28 (2.39) 0.81 (1.49) 0.38 (0.73) 0.48 (0.84) 0.28 (0.59) 0.35 (0.80) 0.43 (0.97) 0.27 (0.56) 0.32 (0.75) 0.37 (0.85) 0.26 (0.64) 
p 0.224 0.830 0.027 0.085 0.568 0.012 0.437 0.879 0.161 0.563 0.826 0.033 
SIM1 rs3734354 G/G(1281) 0.93 (1.84) 1.21 (2.12) 0.67 (1.48) 0.32 (0.69) 0.42 (0.79) 0.22 (0.56) 0.32 (0.72) 0.40 (0.83) 0.25 (0.59) 0.29 (0.70) 0.39 (0.81) 0.20 (0.57) 
G/T(416) 0.97 (1.77) 1.23 (2.13) 0.65 (1.13) 0.33 (0.68) 0.42 (0.83) 0.22 (0.41) 0.36 (0.75) 0.44 (0.89) 0.26 (0.54) 0.28 (0.70) 0.37 (0.82) 0.18 (0.48) 
T/T(26) 1.56 (3.23) 2.79 (4.06) 0.13 (0.31) 0.62 (1.30) 1.07 (1.65) 0.08 (0.19) 0.54 (1.30) 0.96 (1.68) 0.04 (0.14) 0.40 (0.85) 0.75 (1.05) 0 (0) 
p 0.108 0.0035 0.388 0.019 0.0004* 0.592 0.160 0.019 0.490 0.580 0.180 0.534 
ARNT2 rs3901896 C/C(633) 0.95 (1.79) 1.40 (2.31) 0.55 (0.99) 0.33 (0.73) 0.51 (0.94) 0.16 (0.41) 0.33 (0.70) 0.45 (0.88) 0.22 (0.47) 0.30 (0.67) 0.45 (0.83) 0.17 (0.43) 
C/T(825) 0.93 (1.89) 1.13 (2.12) 0.73 (1.61) 0.30 (0.64) 0.35 (0.70) 0.25 (0.58) 0.34 (0.79) 0.42 (0.90) 0.27 (0.64) 0.29 (0.73) 0.37 (0.82) 0.21 (0.61) 
T/T(257) 1.01 (1.87) 1.20 (2.04) 0.75 (1.58) 0.41 (0.79) 0.50 (0.88) 0.29 (0.64) 0.32 (0.67) 0.37 (0.75) 0.25 (0.54) 0.28 (0.70) 0.34 (0.75) 0.20 (0.63) 
p 0.903 0.502 0.409 0.269 0.150 0.046 0.805 0.742 0.839 0.747 0.443 0.808 
CD38 rs6449182 C/C(1031) 0.95 (1.87) 1.25 (2.22) 0.67 (1.42) 0.32 (0.70) 0.44 (0.84) 0.21 (0.52) 0.33 (0.74) 0.41 (0.88) 0.25 (0.57) 0.30 (0.72) 0.40 (0.84) 0.21 (0.58) 
C/G(597) 0.99 (1.88) 1.25 (2.16) 0.70 (1.44) 0.36 (0.73) 0.45 (0.82) 0.26 (0.59) 0.35 (0.77) 0.43 (0.89) 0.26 (0.60) 0.28 (0.67) 0.37 (0.77) 0.18 (0.52) 
G/G(72) 0.53 (0.80) 0.76 (0.97) 0.29 (0.51) 0.13 (0.29) 0.13 (0.31) 0.11 (0.27) 0.24 (0.42) 0.36 (0.49) 0.13 (0.30) 0.16 (0.36) 0.26 (0.47) 0.06 (0.16) 
p 0.147 0.351 0.584 0.044 0.089 0.357 0.518 0.872 0.732 0.280 0.501 0.411 
Overall results of the tests for any associations between SNPs and any ASD symptoms, and mean scores (total and for each sub-domain). P-values ≤0.05 are shown in bold. P-values significant after correction for multiple 
testing (p ≤ 0.0009) are marked with an asterisk. 
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